More than 13,500 people contracted COVID-19 in Connecticut between Aug. 1 and Oct. 5, according to the most recent state data ...

Molnupiravir speeds up recovery and eases long-term symptoms, but its minimal effect on hospitalizations raises questions about its broader impact on COVID-19 care. Study: Health outcomes 3 months ...

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...

New data published yesterday in Morbidity and Mortality Weekly Report (MMWR) show older adults continue to be hospitalized ...

Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has ...

Molnupiravir is the first oral antiviral treatment for Covid to report clinical trial results. The first pill designed to treat symptomatic Covid has been approved by the UK medicines regulator.

A new COVID variant, XEC, has arrived just before fall. The new variant has sprouted from the Omicron variant that developed ...

The pill, an antiviral drug called molnupiravir, was tested against a placebo in people at high risk of developing severe disease. Of the 377 people who got the placebo, 14.1 percent, or 53 ...

Molnupiravir was given to people twice a day, for five days at home, while they had the Omicron variant of Covid. Those chosen were at a higher risk of death or hospitalisation from Covid due to ...

Today, Wedgewood announces the addition of molnupiravir to its formulary. Originally developed for human viral infections, including COVID-19, molnupiravir has emerged as a promising option for ...

New research has found that molnupiravir offers modest longer term benefits to vaccinated adults. This is the latest outcome of the NIHR funded and delivered PANORAMIC trial, led by the University of ...